Abstract A randomized, double-blind, placebo-controlled, cross-over, dose-escalating, single-center study was conducted to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple once-daily (qd) subcutaneous (sc) doses of pasireotide in healthy male subjects. Subjects received pasireotide 50, 200, or 600 lg sc qd for 14 days and placebo in separate sequences. Thirty-three subjects were randomized. The most frequently reported drug-related adverse events were injection-site reactions (n = 18), diarrhea (n = 14) and nausea (n = 10), which were mostly mild or moderate in intensity. Pasireotide 600 lg sc was associated with pre-and post-prandial elevations in glucose levels relative to placebo; however, this effect was less pronounced on day 14 compared with day 1. PK steady state appeared to be achieved after 3 days of dosing and PK exposures had a moderate accumulation of 20-40 % across doses. Pasireotide demonstrated fast absorption (T max,ss : 0.25-0.5 h), low clearance (CL/F ss : 8.10-9.03 L/h), long effective half-life (T ,eff : *12 h, on average between 9.7 and 13.1 h for 50, 200, and 600 lg sc qd), and large volume of distribution (V z /F ss : 251-1,091 L) at steady state. Dose proportionality was confirmed for C max,ss ; other PK parameters (C max , AUC 0-24 h and AUC tau ) were approximately dose proportional. Growth hormone inhibition was observed with pasireotide 200 and 600 lg sc qd. Gallbladder volume increased post-prandially with pasireotide 200 and 600 lg sc qd, which appeared to correlate with reduced levels of cholecystokinin at these doses. Pasireotide was generally well tolerated up to the tested dose of 600 lg qd, with a linear and time-independent PK profile after sc qd dosing in healthy subjects.
Introduction
Somatostatin receptor subtypes are expressed at high levels in many tumor cells, which provides the rationale for the development of medical therapies that specifically target these receptors [1] [2] [3] . Pasireotide (SOM230) is a multireceptortargeted somatostatin analog that binds with high affinity to four of the five somatostatin receptor subtypes (sst 1,2,3 and sst 5 ). Compared with octreotide, pasireotide has a 39-, 30-and 5-fold higher binding affinity for sst 5 , sst 1 and sst 3 , respectively, and a slightly lower (0.4-times lower) binding affinity for sst 2 [3] . Pasireotide also has a 2-fold higher binding affinity for sst 5 than endogenous somatostatin [4] .
The unique binding profile of pasireotide offers potential therapeutic benefits in the indications associated with sst 2 for somatostatin analogs (e.g., octreotide and lanreotide), such as acromegaly [5, 6] and neuroendocrine tumors (NET) [7] [8] [9] . The multireceptor binding profile of pasireotide also provides a rationale for its potential use as a tumor-targeted management option for diseases in which somatostatin receptor subtypes other than sst 2 are involved, e.g., other pituitary adenomas, such as corticotroph adenomas (Cushing's disease, where sst 5 is abundantly expressed) [4] .
Data from pre-clinical studies have shown that the inhibitory effects of pasireotide on the secretion of growth hormone (GH) and subsequent production of insulin-like growth factor 1 (IGF-1) are more potent and are of longer duration than those of octreotide, and that pasireotide effectively inhibits the release of adrenocorticotropic hormone (ACTH) from human corticotroph adenoma cells with or without glucocorticoid pre-treatment [10, 11] . Pasireotide also significantly suppressed cell proliferation and ACTH secretion in primary cultures of human corticotroph tumors [12] . Based on these promising preclinical results, a series of clinical studies for pasireotide were initiated [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] .
This article presents the results of a randomized, doubleblind, placebo-controlled, cross-over, dose-escalating, single-center Phase I study to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple once-daily (qd) subcutaneous (sc) doses of pasireotide in healthy volunteers.
Methods

Subjects
Healthy male subjects aged 18-40 years with normal findings from evaluations performed at screening (e.g., physical examination, vital signs, electrocardiogram [ECG] , and laboratory tests) were enrolled. Subjects' body mass index (BMI) must have been within ±15 kg/m 2 of normal according to the Metropolitan Life Insurance Tables [26] . Subjects were excluded if they used any prescription drug or over-the-counter medication 14 days prior to dosing, participated in any clinical investigation within 4 weeks or had donated or lost C400 mL of blood within 8 weeks prior to dosing. Subjects were also excluded if they had a history of autonomic dysfunction, acute or chronic bronchospastic disease, clinically significant drug allergy, or any surgical or medical condition that significantly altered the absorption, distribution, metabolism, or excretion of drugs (e.g., history of cholecystitis or gallstones, pancreatic injury or pancreatitis, clinical evidence of liver disease or injury as indicated by abnormal liver function tests, history of impaired renal function, evidence of urinary obstruction or difficult voiding at screening, or polymorphonuclear leukocytes \1,500/lL or platelets \100,000/lL at inclusion).
The study was approved by the independent ethics committee, research ethics board or institutional review board at the center and complied with the International Conference of Harmonization (ICH), Harmonized Tripartite Guidelines for Good Clinical Practice, the Declaration of Helsinki and local laws. All subjects provided written informed consent.
Study design
Thirty male subjects were to be randomized into one of two treatment sequences (pasireotide followed by placebo or placebo followed by pasireotide) within three dose-level cohorts (n = 10 in each cohort). Subjects received either pasireotide 50, 200, or 600 lg sc qd. Study medication was injected in the abdominal wall by study center personnel each day between 08:00 am and 09:00 am. Subjects received a daily dose of pasireotide or placebo for 14 days (treatment period 1). Twenty-four hours after the final drug administration in treatment period 1, subjects entered a minimum 14-day washout period. Subjects then received the other treatment (placebo or, respectively, pasireotide) for an additional 14 days (treatment period 2; Fig. 1 ).
Outcomes and assessments
The primary objective was to assess the safety and tolerability of multiple doses of pasireotide sc in healthy subjects. Adverse events (AEs) and serious AEs (SAEs) were recorded throughout the study period. Blood chemistry, hematology and urine values, laboratory tests, ECG measurements, vital signs and physical examination results were recorded. The secondary objectives were to characterize the PK profile of multiple doses of pasireotide sc and to investigate the effects of pasireotide on a number of pharmacodynamic (PD) parameters as indicators of biologic activity.
Blood samples for the PK evaluation were collected predose and then 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 , and 24 h after the first injection in each treatment period. The same sampling times were used after the last administration in each treatment period, with additional samples at 36, 48, 72, and 96 h. Blood samples for trough concentrations were collected pre-dose on days 3, 4, 5, 9, 12, and 13 in each treatment period. All blood samples were collected by either direct venipuncture or indwelling cannula inserted in a forearm vein. A total of 2.5 mL of blood was collected to yield approximately 1 mL of plasma for analysis of pasireotide concentration. Laboratory samples for PK analysis were analyzed by the Department of Bioanalytics and Pharmacokinetics (Novartis Pharma AG, Basel, Switzerland). Plasma concentrations were determined by a validated radioimmunoassay (RIA) with a lower limit of quantification (LLOQ) of 0.03 ng/mL.
PK non-compartmental analysis was performed using WinNonlin software (version 5.2; Pharsight Corp., Endocrine (2012) Mountain View, CA, USA). PK parameters after the first administration on day 1 included: maximum (peak) observed plasma concentration (C max ), time to reach C max (T max ), area under the plasma concentration-time curve from time zero to 24 h (AUC 0-24 h ), and apparent total body clearance (CL/F). PK parameters after the last administration on day 14 included: maximum steady-state drug concentration (C max,ss ), minimum concentration at steady state (C min,ss ), mean concentration at steady state (C avg,ss ), time to reach C max,ss (T max,ss ), area under the plasma concentration-time curve at steady state during one dosing interval (AUC tau,ss = AUC 0-24 h,ss ), apparent total body clearance at steady state (CL/F ss ), apparent volume of distribution at steady state (V z /F ss ), effective half-life (T ,eff ) at steady state, accumulation ratio at steady state (R acc ), and peak-to-trough fluctuation at steady state (=C max,ss /C min,ss 9 100 %). The effective half-life (T ,eff ) of pasireotide was determined by the following equation [27] :
, where s (tau) is the dosing interval (24 h) and R acc is the AUC accumulation ratio, AUC 0-24 h,d14 /AUC 0-24 h,d1 .
For the PD analyses, a GH-releasing hormone (GHRH) stimulation test was performed between 11:00 am and 12:00 pm on study days 2, 13, 30, and 41. Blood samples for evaluation of GH levels were collected at 1 and 30 min before GHRH injection and every 30 min for 2 h (30, 60, 90, and 120 min) after GHRH injection. Glucose, insulin, cholecystokinin (CCK), glucagon, gastrin, and gallbladder contraction profiles were measured on days 1, 14, 29, and 42. Measurements were performed at 1 and 30 min before a standardized meal and every 30 min for 2 h (30, 60, 90, and 120 min) after a standardized meal. For stool fat analysis, stools were collected over two 3-day periods during both treatment periods. Laboratory samples for PD analysis were processed at the Institute of Experimental Clinical Research, Medical Research Laboratories (Aarhus Kommunehospital, Aarhus University Hospital, Aarhus, Denmark).
Statistical methods
Descriptive statistics were generated for demographic variables such as age, weight, height, sex and race, as well as for PK parameters. Dose proportionality for C max , AUC 0-24 h , C max,ss and AUC tau,ss was evaluated using the power model (PK = aÁDose b ), and by comparing the estimated slope b with the critical region 0.91-1.09 [28] .
Results
Thirty healthy male subjects were initially randomized in the study, with 10 subjects in each treatment group. Of the 30 initial subjects, 25 completed the study and five prematurely discontinued the study. Three additional subjects were randomized to replace the subjects who dropped out, with all three completing the study (Table 1 ). In total, 28 subjects completed the study.
One subject withdrew from the study because of drugrelated vomiting of moderate intensity after receiving the first dose of pasireotide 600 lg. Four additional subjects discontinued the study (two withdrew consent, one had a protocol violation, and one had an AE not related to the study medication [severe lumbago]). All subjects who received at least one dose of study drug (n = 33) were included in the safety and tolerability, and PD evaluations. The PK analysis population included 31 subjects on day 1 and 28 subjects on day 14. All subjects except one experienced at least one AE during the study. The most frequent AEs were gastrointestinal symptoms (abdominal pain, nausea, vomiting, and diarrhea), which occurred in a similar percentage of subjects with pasireotide and placebo, and administration site reactions (bruising, erythema, irritation, and pruritus), which occurred predominantly during pasireotide treatment compared with placebo. The majority of AEs were mild to moderate in intensity. Ten subjects experienced nausea after receiving pasireotide 200 or 600 lg. Three subjects receiving 200 lg reported mild-to-moderate nausea, which started within 10 min of injection and lasted for 10 and 45 min, and 4 days. At 600 lg, seven subjects experienced mild-to-moderate nausea, starting approximately 10-15 min after injection and lasting 1-12 h. Five subjects experienced mild-tomoderate vomiting, after receiving pasireotide 600 lg. This occurred primarily on days 1 and 2, although two subjects experienced vomiting on day 14. Five subjects experienced severe AEs, including back pain, abdominal distension, erythema, injection-site irritation and headache, of which back pain and headache were considered not to be related to the study drug. Twenty-seven subjects experienced at least one AE that was considered to be related to the study drug. The most frequently reported drug-related AEs were injection-site reactions, diarrhea, nausea, and vomiting (Table 2) 
Pharmacokinetics
Pasireotide was absorbed rapidly following the first dosing, and C max was observed mostly within 30 min post-injection ( Fig. 2 ; Table 3 ). The systemic drug exposure of pasireotide appeared to increase proportionally with dose escalation ( Fig. 2; Table 3 ). It appeared that pasireotide plasma concentrations reached steady state after 3 days of daily injections, as indicated by similar mean trough concentrations between day 3 and day 14 (Table 3) . At steady state, the peak plasma concentration (C max,ss ) of pasireotide mostly occurred within 30 min of administration ( Fig. 2; Table 3 ). Pasireotide had a long T ,eff (approximately 12 h on average) across the three doses: pasireotide 50 lg: 10.4 ± 3.4 h; pasireotide 200 lg: 9.7 ± 3.4 h; pasireotide 600 lg: 13.1 ± 3.7 h ( Table 3 ). The CL/F ss was low and similar across all three doses (range 8.10 ± 2.14 to 9.03 ± 1.37 L/ hour; Table 3 ). Pasireotide had a large V z /F ss , which BMI body mass index, SD standard deviation Table 2 Adverse events with a suspected study-drug relationship appeared to be increased at higher doses (range up to 1,091 ± 656 L; Table 3 ). 
Pharmacodynamics
GH levels
The ability of pasireotide to decrease GH secretion was demonstrated during a GHRH stimulation test. Inhibition of GHRH-stimulated GH secretion was observed with pasireotide 200 and 600 lg sc (Fig. 3 ). An average pasireotide concentration of approximately 0.4 lg/L yielded half of the maximal GH reduction (EC 50 ), based on an inhibitory E max Pasireotide plasma concentration (ng/mL) Data are median (range) for T max,ss , and arithmetic mean ± SD for all parameters AUC 0-24 h,ss (=AUC tau,ss ) area under the plasma concentration-time curve at steady state during one dosing interval (tau) of 24 h, C avg ss mean steady-state drug concentration, CL/F apparent total body clearance, CL/F ss apparent total body clearance at steady state, T max,ss time to reach peak or maximum concentration following drug administration at steady state, C max,ss maximum steady-state drug concentration, C min,ss minimum steady-state concentration, R acc AUC accumulation ratio, T ,eff effective half-life, V z /F ss apparent volume of distribution at steady state associated with the terminal disposition phase model. GH inhibition was similar on days 2 and 13 ( Fig. 3a, b ).
Blood glucose metabolism
There were minimal changes in post-prandial glucose (0-2 h), insulin or glucagon levels on days 1 and 14 in the pasireotide 50 and 200 lg treatment groups compared with placebo (Table 4 ). In the pasireotide 600 lg group, postprandial glucose and insulin levels (0-2 h) were higher on days 1 and 14 compared with placebo; however, postprandial glucose levels (0-2 h) in the pasireotide 600 lg group were lower on day 14 than day 1. There were no clinically significant shifts in the 2-h post-prandial glucose levels as all subjects in the study had a shift of\140 mg/dL with both placebo and pasireotide (50, 200, and 600 lg) on day 1 and day 14. Subjects receiving pasireotide 600 lg sc had lower glucagon levels than subjects receiving placebo on day 1, but a higher glucagon level on day 14, although there was only one subject in each group.
Cholecystokinin levels
With pasireotide 200 lg, CCK levels were reduced on average by 38-51 % (i.e., mean decreases of -1 to -0.6 pmol/L) compared with placebo between 30 min preand post-lunch on day 1. By day 14, there were no noticeable differences in CCK levels between pasireotide and placebo subjects relative to day 1. Reductions in CCK levels for pasireotide 600 lg compared with placebo were similar at days 1 and 14, with differences ranging on average between 21 and 53 % (i.e., mean decreases of 0.3-1.3 pmol/L) from 30 min pre-lunch to 120 min postlunch.
Gallbladder volume
Gallbladder volume increased for all pasireotide doses compared with placebo, with a greater volume increase observed with higher pasireotide doses (Fig. 4) . The average increases were: pasireotide 50 lg: between 1.1 mL (28.6 %) and 5.3 mL (161.6 %); pasireotide 200 lg: between 15.9 mL (150.3 %) and 18.7 mL (450.1 %); pasireotide 600 lg: between 11.6 mL (1,154.8 %) and 19.4 mL (711.7 %). Table 4 Mean AUC (0-2 h) ± SD for post-prandial glucose, insulin, and glucagon levels Post-prandial glucose 
Stool fat
The difference in the percentage of stool fat increased with higher pasireotide doses. The differences compared with placebo were: pasireotide 50 lg: between -0.3 and 2.9 %; pasireotide 200 lg: between 2.0 and 4.9 %; pasireotide 600 lg: between 4.7 and 7.7 %.
Gastrin and thyroid hormones
No significant differences in gastrin levels and thyroid hormone levels were observed for any pasireotide sc doses compared with placebo.
Discussion
This study evaluated the safety, tolerability, and PK of pasireotide sc in healthy male volunteers. Pasireotide 50, 200, and 600 lg sc administered qd for 14 days was generally well tolerated. AEs were mostly mild or moderate in intensity and gastrointestinal in nature. A total of 10 subjects treated with pasireotide 200 or 600 lg experienced nausea, which occurred within 15 min of injection and lasted between 10 min and 4 days. In the five subjects who reported vomiting during the study, this was transient, occurring predominantly on days 1 and 2. All AEs resolved without clinical intervention and no SAEs or deaths were recorded in this study. AEs considered to be potentially drug related were also mostly gastrointestinal and mild or moderate in intensity. No clinically significant changes in laboratory parameters, vital signs and ECG findings were reported during the study period. PK steady state seemed to be achieved after 3 days of daily pasireotide sc injections and PK exposures were approximately dose proportional on day 1 after a single dose and on day 14 at steady state. The T max and CL/ F values were similar between days 1 and 14, suggesting linear and time-independent PK of pasireotide sc. In addition, the approximate 12-h (mean 9.7-13.1 h across doses) effective half-life (T ,eff ) of pasireotide is longer than that of octreotide sc (*1.7 h [14] ), which suggests that it is suitable for a twice-daily dosing regimen. Phase II and III trials investigating the clinical efficacy and safety of twice-daily (bid) pasireotide sc, as well as a long-acting repeatable formulation (pasireotide LAR), in patients with acromegaly, Cushing's disease, NET and other solid tumors that express multiple somatostatin receptor subtypes are currently ongoing [18] [19] [20] [21] [22] [23] [24] 29] . The results of the Phase I study reported here were obtained (although not published) prior to the Phase II trials discussed above [18, 19, 23, 24] and contributed toward the establishment of the pasireotide bid dosing regimen.
As expected for this class of compound, pasireotide had an effect on glucose metabolism. Single doses of pasireotide 600 lg sc were associated with pre-and post-prandial elevations in glucose levels relative to placebo on day 1. Glucose levels on day 14 were lower than on day 1 in pasireotide 600 lg sc recipients (mean post-prandial glucose AUC (0-2 h) of 212.8 versus 231.7 h mg/dL), but higher than glucose levels on day 14 in placebo recipients. This suggests that increases in glucose levels are transient. Similar elevations in blood glucose levels following pasireotide administration have been reported in patients with Cushing's disease [18] . The potential clinical impact of pasireotide-associated hyperglycemia in patients with pre-existing diabetes or glucose intolerance has been discussed elsewhere in the literature [30] . Compared with day 1, post-prandial insulin levels on day 14 were generally elevated in all groups. This is in contrast to other studies, where insulin levels have been observed to be lower in the post-prandial period [15] . A study in healthy volunteers confirmed that administration of pasireotide is related to decreases in insulin secretion, with no changes in insulin sensitivity [31] .
Pasireotide 200 and 600 lg inhibited GHRH-stimulated GH secretion, as expected for this somatostatin analog. This effect was similar on days 1 and 14, indicating a Time relative to dose administration (hours) Fig. 4 Mean gallbladder volume ± SD over time at a day 1 and b day 14. Placebo treatment is shown as a summary of placebo values at all three treatment levels sustained effect. Gallbladder volume increased for all doses of pasireotide, with a greater increase observed for higher pasireotide doses. The post-prandial increase in gallbladder volume appeared to correlate with reduced levels of CCK at these doses. The increase in gallbladder volume was similar in subjects receiving both pasireotide 200 and 600 lg, while CCK levels were reduced to a greater extent after pasireotide 600 lg than pasireotide 200 lg. This suggests that only a slight reduction in CCK levels is sufficient to significantly delay gallbladder contractions, or it could indicate that pasireotide acts through another mechanism to decrease contractions. Further studies are required to confirm this. The incidence of fatty stools was more prevalent in subjects receiving higher doses of pasireotide (200 and 600 lg); however, there was no effect on overall stool weight at any dose. Pasireotide did not have any effect on gastrin and thyroid hormone secretion.
Conclusions
Pasireotide was generally well tolerated at doses up to 600 lg sc qd and the PK results showed a dose-proportional and time-independent PK profile after qd dosing of pasireotide sc in healthy male subjects. Based on these results, further studies have been undertaken to evaluate the tolerability of pasireotide sc at doses C600 lg administered once or twice daily. Investigation is also under way into the clinical efficacy and safety of pasireotide in patients with acromegaly, Cushing's disease, NET, and other solid tumors that express multiple somatostatin receptor subtypes.
